1.14
0.04 (4.13%)
| Previous Close | 1.09 |
| Open | 1.11 |
| Volume | 203,159 |
| Avg. Volume (3M) | 1,654,414 |
| Market Cap | 7,930,574 |
| Price / Earnings (TTM) | 0.000 |
| Price / Sales | 0.340 |
| Price / Book | 0.330 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -57.62% |
| Operating Margin (TTM) | -43.15% |
| Diluted EPS (TTM) | 1,212.10 |
| Quarterly Revenue Growth (YOY) | -7.90% |
| Total Debt/Equity (MRQ) | 153.49% |
| Current Ratio (MRQ) | 0.680 |
| Operating Cash Flow (TTM) | -15.07 M |
| Levered Free Cash Flow (TTM) | -11.28 M |
| Return on Assets (TTM) | -32.44% |
| Return on Equity (TTM) | -385.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Tobacco (US) | Bullish | Bullish |
| Tobacco (Global) | Bullish | Bullish | |
| Stock | 22nd Century Group, Inc | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.50 |
|
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment. |
|
| Sector | Consumer Defensive |
| Industry | Tobacco |
| Investment Style | Small Value |
| % Held by Insiders | 14.60% |
| % Held by Institutions | 2.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Truvestments Capital Llc | 30 Sep 2025 | 2 |
| Pandora Wealth, Inc. | 30 Sep 2025 | 2 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Dec 2025 | Announcement | 22nd Century to Participate in the Emerging Growth Conference on December 10, 2025 |
| 26 Nov 2025 | Announcement | Emerging Growth Research Releases Q3 2025 Update Report on 22nd Century Group |
| 04 Nov 2025 | Announcement | 22nd Century Group Reports Third Quarter 2025 Financial Results |
| 28 Oct 2025 | Announcement | 22nd Century Announces Receipt of $9.5 Million from Settlement of Insurance Claim |
| 23 Oct 2025 | Announcement | 22nd Century Launches VLN® with Major C-Store Chain, New Marketing Collateral, Continues to Expand State Authorizations |
| 21 Oct 2025 | Announcement | 22nd Century Group to Announce Third Quarter 2025 Results on November 4, 2025 |
| 30 Sep 2025 | Announcement | 22nd Century Submits Comments to FDA in Support of Proposed Reduced Nicotine Content Mandate |
| 24 Sep 2025 | Announcement | 22nd Century Secures $9.5 Million Cash Proceeds from Settlement of Insurance Claim |
| 18 Sep 2025 | Announcement | 22nd Century Announces Debt-Free Balance Sheet and New Growth Capital |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |